Quick Answer
Clearside Biomedical, Inc. reported Total Assets of $25.13 million for the year ending 2024.
- Clearside Biomedical, Inc. showed a decrease of -26.1% in Total Assets from 2023 to 2024.
- This data is from Clearside Biomedical, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $56.16 million | Q3 2016: $57.77 million | Q1 2017: $81.96 million | Q2 2017: $68.42 million | Q3 2017: $54.88 million | Q1 2018: $104.46 million | Q2 2018: $88.02 million | Q3 2018: $69.38 million | Q1 2019: $37.53 million | Q2 2019: $29.85 million | Q3 2019: $25.87 million | Q1 2020: $25.04 million | Q2 2020: $17.74 million | Q3 2020: $17.41 million | Q1 2021: $27.82 million | Q2 2021: $28.59 million | Q3 2021: $27.38 million | Q1 2022: $36.06 million | Q2 2022: $30.75 million | Q3 2022: $55.69 million | Q1 2023: $44.70 million | Q2 2023: $39.19 million | Q3 2023: $34.42 million | Q1 2024: $40.14 million | Q2 2024: $33.93 million | Q3 2024: $29.16 million | Q4 2024: $25.13 million | Q1 2025: $19.67 million | Q2 2025: $15.33 million | Q3 2025: $11.64 million.
- Over the full 10 years of available data (2015 to 2024), Clearside Biomedical, Inc.'s Total Assets has grown by 19.3%.
- Historical annual values: Fiscal year 2024: $25.13 million | Fiscal year 2023: $34.02 million | Fiscal year 2022: $51.30 million | Fiscal year 2021: $42.90 million | Fiscal year 2020: $19.32 million | Fiscal year 2019: $26.78 million | Fiscal year 2018: $44.12 million | Fiscal year 2017: $40.49 million | Fiscal year 2016: $84.81 million | Fiscal year 2015: $21.06 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: